Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib

Am J Manag Care. 2012 May;18(5 Spec No. 2):SP84-7.

Author

Nathan A Pennell¹

Affiliation

¹ Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.

PMID: 22693986

No abstract available

MeSH terms

Adult
Anaplastic Lymphoma Kinase
Antineoplastic Agents / economics
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / economics
Carcinoma, Non-Small-Cell Lung / genetics
Crizotinib
Drug Approval
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / economics
Lung Neoplasms / genetics
Male
Protein Kinase Inhibitors / economics
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
United States
United States Food and Drug Administration
Young Adult

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Pyrazoles
Pyridines
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases